，成果详细信息-凯发网

in this study, we designed biodegradable polymersomes for co-delivery of an antiangiogenic drug combretastatin-a4 phosphate (ca4p) and doxorubicin (dox) to collapse tumor neovasculature and inhibit cancer cell proliferation with the aim to achieve synergistic antitumor effects. the polymersomes co-encapsulating dox and ca4p (ps-dox-ca4p) were prepared by solvent evaporation method using methoxy poly(ethylene glycol)-b-polylactide (mpeg-pla) block copolymers as drug carriers. the resulting ps-dox-ca4p has vesicles shape with uniform sizes of about 50 nm and controlled co-encapsulation ratios of dox to ca4p. more importantly, ps-dox-ca4p (1:10) showed strong synergistic cytotoxicity (combination index ci = 0.31) against human nasopharyngeal epidermal carcinoma (kb) cells. furthermore, ps-dox-ca4p accumulated remarkably in kb tissues xenografts in nude mice. consistent with these observations, ps-dox-ca4p (1:10) achieved significant antitumor potency because of fast tumor vasculature disruption and sustained tumor cells proliferation inhibition in vivo. the overall findings indicate that co-delivery of an antiangiogenic drug and a chemotherapeutic agent in polymersomes is a potentially promising strategy for cancer therapy.